Nautilus Biotechnology, Inc.
NAUT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $2 | $2 | $2 | $6 |
| Gross Profit | -$2 | -$2 | -$2 | -$6 |
| % Margin | – | – | – | – |
| R&D Expenses | $9 | $10 | $11 | $11 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $5 | $6 | $6 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $14 | $15 | $17 | $14 |
| Operating Income | -$15 | -$17 | -$19 | -$20 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2 | $2 | $2 | $2 |
| Pre-Tax Income | -$14 | -$15 | -$17 | -$18 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$14 | -$15 | -$17 | -$18 |
| % Margin | – | – | – | – |
| EPS | -0.11 | -0.12 | -0.13 | -0.14 |
| % Growth | 8.3% | 7.7% | 7.1% | – |
| EPS Diluted | -0.11 | -0.12 | -0.13 | -0.14 |
| Weighted Avg Shares Out | 126 | 126 | 125 | 126 |
| Weighted Avg Shares Out Dil | 126 | 126 | 125 | 126 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $2 | $2 | $2 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $2 | $2 | $6 |
| EBITDA | -$12 | -$13 | -$15 | -$11 |
| % Margin | – | – | – | – |